Phenibut – a new development stage of the novel nootropic drugs

According to the World Health Organization (WHO), around 7 million cerebral strokes cases and 1.4 million craniocereberal trauma cases are recorded globally every year. Only 10% of survivors with these pathologies return to their previous work; Only 25% of those who had a stroke or had a BMI were satisfied with the quality of life. Also in recent years, the number of the elderly planet population has increased, which leads to an increase in the incidence of neurological diseases that develop at this age (neurodegenerative dementia and cognitive disorders associated with cerebrovascular diseases (discirculatory encephalopathy). Different nervous system diseases provide the use of nootropic drugs. According to WHO statistics, one third of the adult population in Europe and Japan Nima nootropics.
The main feature of this drugs group is the influence on the biochemical processes underlying the intellectual-mnestic functions realization (regulation of cognitive functions, memory, learning). In addition, among the pharmacological effects of nootropics, one of the leading places is occupied by cerebro- and stress-protective action, which determines the expediency of their use also in healthy people. As a result, the latitude of indications for the use of nootropics exceeds the analogous indications for other neurotropic agents. So, these drugs are very popular and used for various neurological diseases, brain injuries, mental illness, chronic alcoholism. Currently, nootropics are also used to treat somatogenies, asthenic depressions, asthenic and hypersomnical conditions, as well as for cupping and prophylaxis of cardio-neurotic and neurasthenic (arterial hypotension, dizziness, fainting, irritable weakness) of the syptomocomplexes.
However, possible side effects of nootropic pharmacotherapy should be considered, manifested mainly by increased excitability, irritability, anxiety, aggressiveness, sleep disorders, tremor, nausea, vomiting, dyspepsia.
To date, special interest is the possibility of using new generation nootropic drugs, possessing a wide spectrum of psychopharmacotherapeutic activity, including not only a direct activating effect on cognitive functions (learning, memory, mental activity), but also anxiolytic, anti-asthenic, timoleptic and others effects.
Advantage among the means of this group should be given to phenibut, since it has optimal psychotherapeutic characteristics and minimal somatotoxicity. Phenibut, which is hydrochloride beta-phenyl-gamma-aminobutyric acid, was synthesized by Soviet professor VV Perekalin and studied at the Experimental Medicine Institute of the Medical Sciences USSR Academy. In 1975, the phenibut preparation was already included in the first aid kit of cosmonauts participating in the Soyuz-Apollo experimental flight, since benzodiazepine tranquilizers, which in addition to calming effect, exert a depressing effect on the central nervous system, reduced the efficiency and attention of cosmonauts. With the Phenibut reception, the cosmonauts’ working capacity remained at the same level.
Phenibut has a direct effect on GABAergic receptors, facilitates GABA-mediated nerve impulses transmission in the central nervous system. Improves the brain functional state due to the normalization of tissue metabolism and effects on cerebral circulation, also has a tranquilizing, antiaggregant and antioxidant effect. Promotes the reduction or disappearance of anxiety feelings, tension, anxiety and fear, normalizes sleep, has an anticonvulsant effect. Reduces the manifestation of asthenia and manifests vegetative stabilizing effect. At the course reception increases physical and mental efficiency, improves memory, the state of patients with motor and speech disorders.
Phenibut is characterized by a pronounced antihypoxic effect and the ability to increase the glucose content in the brain. Comparative studies have shown that nootropic (antiamnestic and antihypoxic) and vasotropic (elimination of headache, dizziness, autonomic lability) phenibut activity exceeds the piracetam action. At the same time, the phenibut tranquilizing effect is manifested together and in parallel with nootropic activity.
In patients with asthenia, from the first days of therapy with Phenibut, the well-being improves, the interest and initiative (motivation of activity) increases without sedation or excitation. Unlike piracetam and aminolone, phenibut doesn’t exhibit a psychostimulatory effect, which is manifested in increased irritability and anxiety, sleep disturbances, and other undesirable effects. Clinical efficacy of phenibut manifests itself in the first hours and days of treatment, unlike piracetam and aminolone, the effect of which occurs slowly during one to two weeks of treatment.
In the appointment after severe craniocerebral trauma, phenibut increases the number of mitochondria in the perifocal areas and improves the bioenergetic processes course in the brain. Improves microcirculation in the tissues of the eye, reduces the inhibitory effect of ethanol on the central nervous system.
Given the spectrum breadth of clinical action and high safety, phenibut is a means of choice in children’s psychiatry and neurology. Phenibut is used for logoneuroses, functional and organic teats in children. In adults, the drug is used for asthenic and anxiety-neurotic states; with anxiety, fear, obsessive-compulsive disorder, psychopathy; with insomnia, in persons suffering from neurosis, vascular and senile psychoses, with neuroses and reactive psychoses, hypomanic states; for the prevention of anxiety conditions that arise before surgical interventions and painful diagnostic examinations; in the complex treatment of alcoholism (for the relief of psychopathological and somatovegetative disorders with abstinence syndrome); with the aim of potentiating the action of neuroleptics and barbiturates.
The drug is low toxicity. Side effect when taking phenibut is possible at the beginning of treatment (drowsiness, nausea, allergic reactions). Contraindications are hypersensitivity to the drug components, pregnancy, breastfeeding, children under 8 years.
Thus, Phenibut has a balanced, harmonious therapeutic effect: it has antihypoxic, antiamnestic effects, has the properties of a daytime tranquilizer and anticonvulsant, reduces the severity of cognitive disorders, anxiety, fear, normalizes sleep, improves physical and mental performance, eliminates vegetative disorders. The combination of nootropic and soothing effects in this preparation makes it possible to achieve adaptogenic activity, anti-stress and stress-protective action, especially in conditions of worsening cerebral circulation and hypoxia. In terms of efficiency, safety and economy, Phenibut meets the requirements for modern psychotropic drugs, the use of which is permissible in the widest possible range in the neurotic reactions treatment and in the complex therapy of somatic patients. If you’re looking for the best place to buy Phenibut (Anvifen, Fenibut, Noofen) HCL powder online, visit RC’s online store to place an order.

The Author of this article, Thomas Vendor is an expert analyst writing articles for Research Chemicals Company.



Reset Password